Keywords: Janssen-Cilag, Johnson & Johnson, Zytiga, Novartism Votubia, Afinitor, Prostate cancer, SEGA
EU approval for Janssen-Cilag’s Zytiga in prostate cancer and Novartis’ Votubia for SEGA
Article | 08 September 2011
Belgium-based Janssen-Cilag International, a subsidiary of US health care giant Johnson & Johnson (NYSE: JNJ), says that, after an accelerated ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
